home / stock / rigl / rigl quote
Last: | $1.10 |
---|---|
Change Percent: | 0.44% |
Open: | $1.12 |
Close: | $1.10 |
High: | $1.14 |
Low: | $1.06 |
Volume: | 2,960,322 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.1 | $1.12 | $1.1 | $1.14 | $1.06 | 2,960,322 | 04-25-2024 |
$1.125 | $1.13 | $1.125 | $1.156 | $1.11 | 6,448,270 | 04-24-2024 |
$1.14 | $1.13 | $1.14 | $1.17 | $1.12 | 518,836 | 04-23-2024 |
$1.13 | $1.06 | $1.13 | $1.14 | $1.06 | 3,339,868 | 04-22-2024 |
$1.08 | $1.05 | $1.08 | $1.09 | $1.01 | 812,826 | 04-19-2024 |
$1.05 | $1.12 | $1.05 | $1.12 | $1.05 | 1,237,672 | 04-18-2024 |
$1.11 | $1.14 | $1.11 | $1.1599 | $1.105 | 578,022 | 04-17-2024 |
$1.14 | $1.14 | $1.14 | $1.1596 | $1.1 | 754,958 | 04-16-2024 |
$1.15 | $1.19 | $1.15 | $1.19 | $1.14 | 768,566 | 04-15-2024 |
$1.2 | $1.21 | $1.2 | $1.24 | $1.18 | 3,746,766 | 04-12-2024 |
$1.23 | $1.24 | $1.23 | $1.265 | $1.22 | 581,181 | 04-11-2024 |
$1.22 | $1.25 | $1.22 | $1.25 | $1.19 | 892,384 | 04-10-2024 |
$1.25 | $1.28 | $1.25 | $1.3 | $1.22 | 3,445,492 | 04-09-2024 |
$1.26 | $1.315 | $1.26 | $1.315 | $1.22 | 6,360,534 | 04-08-2024 |
$1.29 | $1.29 | $1.29 | $1.305 | $1.255 | 1,411,688 | 04-05-2024 |
$1.29 | $1.36 | $1.29 | $1.36 | $1.275 | 857,128 | 04-04-2024 |
$1.33 | $1.31 | $1.33 | $1.36 | $1.3 | 545,029 | 04-03-2024 |
$1.33 | $1.27 | $1.33 | $1.33 | $1.26 | 800,840 | 04-02-2024 |
$1.34 | $1.44 | $1.34 | $1.445 | $1.175 | 3,723,856 | 04-01-2024 |
$1.48 | $1.47 | $1.48 | $1.505 | $1.46 | 782,389 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net produ...